Lipocine Inc. (LPCN)
4.72
0.12 (2.61%)
At close: Jan 15, 2025, 12:04 PM
undefined% (undefined)
| Bid | 4.72 |
| Market Cap | 25.26M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.75 |
| PE Ratio (ttm) | -6.3 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 4.89 |
| Volume | 25,415 |
| Avg. Volume (20D) | 30,131 |
| Open | 4.85 |
| Previous Close | 4.60 |
| Day's Range | 4.72 - 4.89 |
| 52-Week Range | 3.20 - 11.79 |
| Beta | undefined |
About LPCN
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioident...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 22, 2013
Employees 17
Stock Exchange NASDAQ
Ticker Symbol LPCN
Website https://www.lipocine.com
Analyst Forecast
According to 1 analyst ratings, the average rating for LPCN stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 111.73% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Lipocine Inc. is scheduled to release its earnings on Mar 6, 2025,
before market opens.
Analysts project revenue of $200.00K, reflecting a -7.49% YoY shrinking and earnings per share of -0.38, making a -9.52% decrease YoY.
Analysts project revenue of $200.00K, reflecting a -7.49% YoY shrinking and earnings per share of -0.38, making a -9.52% decrease YoY.
2 months ago ·
Source
-7.76%
Lipocine shares are trading lower. The company rep...
Unlock content with
Pro Subscription
